Activity Date: 04/07/2024
Sign in (or create a FREE account) to access this FREE session!Modulation of dopamine levels in key brain areas affected in schizophrenia has historically been achieved by using dopamine D2 receptor antagonists. Although such D2 receptor blockade may ameliorate positive symptoms of schizophrenia, it often comes at the cost of high motor side effect risk and lack of efficacy for treating the non-positive symptoms of schizophrenia. In this presentation, the speaker will bring to light the intricate neurocircuitry affecting dopaminergic neurotransmission as it relates to schizophrenia. With this understanding, potential utilization of novel agents to modulate dopamine levels without directly affecting dopamine D2 receptors will be discussed and evaluated.
Andrew J. Cutler, MD
View biographical information and disclosuresAAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
The bookmark/discussion system is temporarily disabled. Please check back later.
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Claim Credits
The program evaluation and CME certificate will be available on April 7, 2024.
Questions? email CustomerService@neiglobal.com or phone 888-535-5600 (Mon-Fri: 9am5pm Pacific)